Figma Shares Indicated To Open $105/$110
Investing.com - BofA Securities has raised its price target on Boston Scientific (NYSE:BSX) to $120.00 from $115.00 while maintaining a Buy rating on the medical device maker’s stock. The company, currently trading at $106.88 and near its 52-week high of $107.53, has shown remarkable strength with a 31% return over the past year. InvestingPro data reveals the company maintains a "GREAT" financial health score of 3.06.
The price target adjustment comes after BofA Securities analyst Travis Steed analyzed Boston Scientific’s second-quarter financial results, which included a $100 million impact on the adjusted income statement.
According to the analyst, the majority of this impact—estimated at $60-70 million—came from inventory charges, which directly affected gross margin by approximately 120-140 basis points.
The remaining $30-40 million was attributed to sales returns, which directly impacted revenue but had a less material effect on gross margin, as the TAVR (Transcatheter Aortic Valve Replacement) product line’s gross margin is reportedly not significantly different from Boston Scientific’s corporate average.
BofA Securities noted that while there is no significant margin impact expected from TAVR in the second half of 2025, the company faces a $100 million tariff headwind during that period, which represents a $100 million improvement from the $200 million headwind projected three months ago.
In other recent news, Boston Scientific Corp. reported its second-quarter 2025 earnings, surpassing analysts’ expectations. The company achieved an adjusted earnings per share of $0.75, which was above the forecasted $0.73. Revenue for the quarter came in at $5.06 billion, exceeding the anticipated $4.89 billion. These results highlight the company’s strong financial performance in the recent period. Additionally, the earnings report was followed by an increase in the company’s stock price. While the stock movement is noteworthy, the focus remains on the company’s financial achievements. These developments are part of the recent updates concerning Boston Scientific.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.